You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 245 No. 4, January 23, 1981 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA

Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin

W. R. Wilson, R. L. Thompson, C. J. Wilkowske, J. A. Washington 2nd, E. R. Giuliani and J. E. Geraci

In a prospective study, 91 patients with penicillin-sensitive infective endocarditis (IE) were treated for two weeks with intramuscular (IM) penicillin G procaine, 1.2 million units every six hours, plus streptomycin sulfate, 500 mg IM every 12 hours. Viridans streptococci were isolated from 70 patients (77%); 21 patients (23%) had Streptococcus bovis infections. Eighteen patients (20%) had had symptoms of IE for three months or longer. Follow-up ranged from two months to 6.6 years. There were no relapses; mild vestibular toxic reactions occurred in two patients (2%). Two patients (2%) died--one of sudden-onset severe heart failure and one of cardiac arrest after aortic valve replacement. Twenty-six patients (19%) required cardiac valve replacement after completion of antimicrobial therapy. This therapy seems as efficacious as four weeks of parenteral antimicrobial therapy and is more cost-effective.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Antimicrobial treatment of infective endocarditis caused by viridans streptococci highly susceptible to penicillin: historic overview and future considerations
Verhagen et al.
J Antimicrob Chemother 2006;57:819-824.
ABSTRACT | FULL TEXT  

Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.
Anguita-Alonso et al.
Antimicrob. Agents Chemother. 2006;50:1263-1267.
ABSTRACT | FULL TEXT  

The role of aminoglycosides in combination with a {beta}-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials
Falagas et al.
J Antimicrob Chemother 2006;57:639-647.
ABSTRACT | FULL TEXT  

Culture results of heart valves resected because of streptococcal endocarditis: insights into duration of treatment to achieve valve sterilization
Upton et al.
J Antimicrob Chemother 2005;55:234-239.
ABSTRACT | FULL TEXT  

Association of Streptococcus bovis Bacteremia With Colonic Neoplasia and Extracolonic Malignancy
Gold et al.
Arch Surg 2004;139:760-765.
ABSTRACT | FULL TEXT  

Unique Features of Infective Endocarditis in Childhood
Ferrieri et al.
Pediatrics 2002;109:931-943.
FULL TEXT  

Unique Features of Infective Endocarditis in Childhood
Ferrieri et al.
Circulation 2002;105:2115-2126.
FULL TEXT  

VALVE DISEASE: Endocarditis: basics
Eykyn
Heart 2001;86:476-480.
FULL TEXT  

Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis
Working Party of the British Society for Antimicro
Heart 1998;79:207-208.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.